Accueil CHUV
Navigation menu

Centre de la prostate

Publications

Les intervenants du Centre de la prostate publient chaque année les résultats de leurs travaux de recherche dans diverses revues suisses et internationales.

2023

Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer.

Templeton AJ, Omlin A, Berthold D, Beyer J, Burger IA, Eberli D, Engeler D, Fankhauser C, Fischer S, Gillessen S, Nicolas G, Kroeze S, Lorch A, Müntener M, Papachristofilou A, Schaefer N, Seiler D, Stenner F, Tsantoulis P, Vlajnic T, Zilli T, Zwahlen D, Cathomas R

Swiss Med Wkly. 2023 Aug 15;153:40108

[Prostate cancer in the era of precision medicine: a new horizon].

Nguyen-Ngoc T, Berthold D, Normand C

Rev Med Suisse. 2023 May 17;19(827):950-956

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.

Attard G, Murphy L, Clarke NW, Sachdeva A, Jones C, Hoyle A, Cross W, Jones RJ, Parker CC, Gillessen S, Cook A, Brawley C, Gilson C, Rush H, Abdel-Aty H, Amos CL, Murphy C, Chowdhury S, Malik Z, Russell JM, Parkar N, Pugh C, Diaz-Montana C, Pezaro C, Grant W, Saxby H, Pedley I, O’Sullivan JM, Birtle A, Gale J, Srihari N, Thomas C, Tanguay J, Wagstaff J, Das P, Gray E, Alzouebi M, Parikh O, Robinson A, Montazeri AH, Wylie J, Zarkar A, Cathomas R, Brown MD, Jain Y, Dearnaley DP, Mason MD, Gilbert D, Langley RE, Millman R, Matheson D, Sydes MR, Brown LC, Parmar MKB, James ND, STAMPEDE investigators

Lancet Oncol. 2023 May;24(5):443-456

Toxicity, quality of life, and PSA control after 50 Gy stereotactic body radiation therapy to the dominant intraprostatic nodule with the use of a rectal spacer: results of a phase I/II study.

Cloitre M, Valerio M, Mampuya A, Rakauskas A, Berthold D, Tawadros T, Meuwly JY, Heym L, Duclos F, Vallet V, Zeverino M, Jichlinski P, Prior J, Roth B, Bourhis J, Herrera FG

Br J Radiol. 2023 Apr 1;96(1145):20220803

[Oncology: what’s new in 2022].

Nguyen-Ngoc T, Abdelhamid K, Degrauwe N, Galland S, Serena A, Christofis M, Mederos N, Bouchaab H, Diciolla A, Dris N, Orcurto A, Perrinjaquet C, Schnetz M, Latifyan S, Wetterwald L, Herrera Gómez RG, Cristina V, Sarivalasis A, Michielin O, Berthold D, Digklia A, Wagner AD, Zaman K, Peters S, Stravodimou A

Rev Med Suisse. 2023 Jan 18;19(N° 809-10):52-57
2022

Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).

James ND, Clarke NW, Cook A, Ali A, Hoyle AP, Attard G, Brawley CD, Chowdhury S, Cross WR, Dearnaley DP, de Bono JS, Diaz-Montana C, Gilbert D, Gillessen S, Gilson C, Jones RJ, Langley RE, Malik ZI, Matheson DJ, Millman R, Parker CC, Pugh C, Rush H, Russell JM, Berthold DR, Buckner ML, Mason MD, Ritchie AWS, Birtle AJ, Brock SJ, Das P, Ford D, Gale J, Grant W, Gray EK, Hoskin P, Khan MM, Manetta C, McPhail NJ, O’Sullivan JM, Parikh O, Perna C, Pezaro CJ, Protheroe AS, Robinson AJ, Rudman SM, Sheehan DJ, Srihari NN, Syndikus I, Tanguay JS, Thomas CW, Vengalil S, Wagstaff J, Wylie JP, Parmar MKB, Sydes MR, STAMPEDE Trials Collaborative Group

Int J Cancer. 2022 Aug 1;151(3):422-434

Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2×2 factorial design.

Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fléchon A, Tombal B, Supiot S, Berthold D, Ronchin P, Kacso G, Gravis G, Calabro F, Berdah JF, Hasbini A, Silva M, Thiery-Vuillemin A, Latorzeff I, Mourey L, Laguerre B, Abadie-Lacourtoisie S, Martin E, El Kouri C, Escande A, Rosello A, Magne N, Schlurmann F, Priou F, Chand-Fouche ME, Freixa SV, Jamaluddin M, Rieger I, Bossi A, PEACE-1 investigators

Lancet. 2022 Apr 30;399(10336):1695-1707

Overcoming Immune Resistance With Radiation Therapy in Prostate Cancer.

Mulvey A, Muggeo-Bertin E, Berthold DR, Herrera FG

Front Immunol. 2022;13:859785

[2021 Oncology update].

Meyer ML, Chrysou K, Stamatiou A, Gilabert M, Herrera Gomez RG, Latifyan S, Masmoudi S, Mederos N, Perrinjaquet C, Berthold D, Bouchaab H, Cristina V, Digklia A, Michielin O, Orcurto A, Sarivalasis A, Stravodimou A, Wagner AD, Zaman K, Peters S, Jankovic J

Rev Med Suisse. 2022 Feb 2;18(767):182-186

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.

Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, Gillessen S, Cook A, Brawley C, Amos CL, Atako N, Pugh C, Buckner M, Chowdhury S, Malik Z, Russell JM, Gilson C, Rush H, Bowen J, Lydon A, Pedley I, O’Sullivan JM, Birtle A, Gale J, Srihari N, Thomas C, Tanguay J, Wagstaff J, Das P, Gray E, Alzoueb M, Parikh O, Robinson A, Syndikus I, Wylie J, Zarkar A, Thalmann G, de Bono JS, Dearnaley DP, Mason MD, Gilbert D, Langley RE, Millman R, Matheson D, Sydes MR, Brown LC, Parmar MKB, James ND, Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators

Lancet. 2022 Jan 29;399(10323):447-460

Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy.

Herrera FG, Ronet C, Ochoa de Olza M, Barras D, Crespo I, Andreatta M, Corria-Osorio J, Spill A, Benedetti F, Genolet R, Orcurto A, Imbimbo M, Ghisoni E, Navarro Rodrigo B, Berthold DR, Sarivalasis A, Zaman K, Duran R, Dromain C, Prior J, Schaefer N, Bourhis J, Dimopoulou G, Tsourti Z, Messemaker M, Smith T, Warren SE, Foukas P, Rusakiewicz S, Pittet MJ, Zimmermann S, Sempoux C, Dafni U, Harari A, Kandalaft LE, Carmona SJ, Dangaj Laniti D, Irving M, Coukos G

Cancer Discov. 2022 Jan;12(1):108-133
2021
2019
2018
2017

[Local treatment in oligometastatic urological malignancies : evidence of wishful thinking ?].

Valerio M, Cerantola Y, Lucca I, Berthold D, Jichlinski P

Rev Med Suisse. 2017 Nov 29;13(585):2083-2086

Enzalutamide in Patients With Castration-Resistant Prostate Cancer Progressing After Docetaxel: Retrospective Analysis of the Swiss Enzalutamide Named Patient Program.

Papazoglou D, Wannesson L, Berthold D, Cathomas R, Gillessen S, Rothermundt C, Hasler L, Winterhalder R, Barth A, Mingrone W, Nussbaum CU, von Rohr L, von Burg P, Schmid M, Richner J, Baumann S, Kühne R, Stenner F, Rothschild SI

Clin Genitourin Cancer. 2017 Jun;15(3):e315-e323

Focal therapy as primary treatment for localized prostate cancer: definition, needs and future.

Ouzzane A, Betrouni N, Valerio M, Rastinehad A, Colin P, Ploussard G

Future Oncol. 2017 Apr;13(8):727-741

Magnetic resonance imaging-transrectal ultrasound fusion focal cryotherapy of the prostate: A prospective development study.

Valerio M, Shah TT, Shah P, Mccartan N, Emberton M, Arya M, Ahmed HU

Urol Oncol. 2017 Apr;35(4):150.e1-150.e7

Nanoknife Electroporation Ablation Trial: A Prospective Development Study Investigating Focal Irreversible Electroporation for Localized Prostate Cancer.

Valerio M, Dickinson L, Ali A, Ramachadran N, Donaldson I, Mccartan N, Freeman A, Ahmed HU, Emberton M

J Urol. 2017 Mar;197(3 Pt 1):647-654

New and Established Technology in Focal Ablation of the Prostate: A Systematic Review.

Valerio M, Cerantola Y, Eggener SE, Lepor H, Polascik TJ, Villers A, Emberton M

Eur Urol. 2017 Jan;71(1):17-34
2016

Transperineal template prostate-mapping biopsies: an evaluation of different protocols in the detection of clinically significant prostate cancer.

Valerio M, Anele C, Charman SC, van der Meulen J, Freeman A, Jameson C, Singh PB, Emberton M, Ahmed HU

BJU Int. 2016 Sep;118(3):384-90

The concordance between the volume hotspot and the grade hotspot: a 3-D reconstructive model using the pathology outputs from the PROMIS trial.

El-Shater Bosaily A, Valerio M, Hu Y, Freeman A, Jameson C, Brown L, Kaplan R, Hindley RG, Barratt D, Emberton M, Ahmed HU

Prostate Cancer Prostatic Dis. 2016 Sep;19(3):258-63

Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991.

Bolla M, Maingon P, Carrie C, Villa S, Kitsios P, Poortmans PM, Sundar S, van der Steen-Banasik EM, Armstrong J, Bosset JF, Herrera FG, Pieters B, Slot A, Bahl A, Ben-Yosef R, Boehmer D, Scrase C, Renard L, Shash E, Coens C, van den Bergh AC, Collette L

J Clin Oncol. 2016 May 20;34(15):1748-56

Radiation Therapy after Radical Prostatectomy: Implications for Clinicians.

Herrera FG, Berthold DR

Front Oncol. 2016;6:117

The Prevalence of Clinically Significant Prostate Cancer According to Commonly Used Histological Thresholds in Men Undergoing Template Prostate Mapping Biopsies.

Valerio M, Anele C, Bott SR, Charman SC, van der Meulen J, El-Mahallawi H, Emara AM, Freeman A, Jameson C, Hindley RG, Montgomery BS, Singh PB, Ahmed HU, Emberton M

J Urol. 2016 May;195(5):1403-1408

Role of multiparametric magnetic resonance imaging in early detection of prostate cancer.

De Visschere PJ, Briganti A, Fütterer JJ, Ghadjar P, Isbarn H, Massard C, Ost P, Sooriakumaran P, Surcel CI, Valerio M, van den Bergh RC, Ploussard G, Giannarini G, Villeirs GM

Insights Imaging. 2016 Apr;7(2):205-14

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G, de Bono J, Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, Millman R, Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti P, C

Lancet. 2016 Mar 19;387(10024):1163-77

The challenging landscape of medical device approval in localized prostate cancer.

Valerio M, Emberton M, Eggener SE, Ahmed HU

Nat Rev Urol. 2016 Feb;13(2):91-8

[Novelties in Urology in 2015].

Jichlinski P

Rev Med Suisse. 2016 Jan 13;12(500):95-6

Addressing overtreatment following the diagnosis of localized prostate cancer.

Tawadros T, Valerio M

Expert Rev Anticancer Ther. 2016;16(4):373-4
2015

[Prostate biopsy: which strategy for which patient?].

Burruni R, Cerantola Y, Meuwly JY, Tawadros T, Jichlinski P, Valerio M

Rev Med Suisse. 2015 Dec 2;11(497):2288-90, 2292

[Sharing uncertainties of prostate cancer screening].

Selby K, Auer R, Valerio M, Jichlinski P, Cornuz J

Rev Med Suisse. 2015 Nov 25;11(496):2216, 2218-20

Methodological considerations in assessing the utility of imaging in early prostate cancer.

Valerio M, Willis S, van der Meulen J, Emberton M, Ahmed HU

Curr Opin Urol. 2015 Nov;25(6):536-42

A review of economic evaluations of diagnostic strategies using imaging in men at risk of prostate cancer.

Willis SR, van der Meulen J, Valerio M, Miners A, Ahmed HU, Emberton M

Curr Opin Urol. 2015 Nov;25(6):483-9

Visually directed vs. software-based targeted biopsy compared to transperineal template mapping biopsy in the detection of clinically significant prostate cancer.

Valerio M, McCartan N, Freeman A, Punwani S, Emberton M, Ahmed HU

Urol Oncol. 2015 Oct;33(10):424.e9-16

Consensus and differences in primary radiotherapy for localized and locally advanced prostate cancer in Switzerland: A survey on patterns of practice.

Panje CM, Dal Pra A, Zilli T, R Zwahlen D, Papachristofilou A, Herrera FG, Matzinger O, Plasswilm L, Putora PM

Strahlenther Onkol. 2015 Oct;191(10):778-86

Focal Therapy of Prostate Cancer Using Irreversible Electroporation.

Valerio M, Ahmed HU, Emberton M

Tech Vasc Interv Radiol. 2015 Sep;18(3):147-52

Prostate Cancer Unit Initiative in Europe: A position paper by the European School of Oncology.

Valdagni R, Van Poppel H, Aitchison M, Albers P, Berthold D, Bossi A, Brausi M, Denis L, Drudge-Coates L, De Santis M, Feick G, Harrison C, Haustermans K, Hollywood D, Hoyer M, Hummel H, Mason M, Mirone V, Müller SC, Parker C, Saghatchian M, Sternberg CN,

Crit Rev Oncol Hematol. 2015 Aug;95(2):133-43

Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy: A Systematic Review.

Valerio M, Donaldson I, Emberton M, Ehdaie B, Hadaschik BA, Marks LS, Mozer P, Rastinehad AR, Ahmed HU

Eur Urol. 2015 Jul;68(1):8-19

Is high dose rate brachytherapy reliable and effective treatment for prostate cancer patients? A review of the literature.

De Bari B, Daidone A, Alongi F

Crit Rev Oncol Hematol. 2015 Jun;94(3):360-70

Identifying the index lesion with template prostate mapping biopsies.

Valerio M, Anele C, Freeman A, Jameson C, Singh PB, Hu Y, Emberton M, Ahmed HU

J Urol. 2015 Apr;193(4):1185-90

Technological aspects of delivering cryotherapy for prostate cancer.

Lau B, Shah TT, Valerio M, Hamid S, Ahmed HU, Arya M

Expert Rev Med Devices. 2015 Mar;12(2):183-90

Combination of androgen deprivation therapy and radiotherapy for localized prostate cancer in the contemporary era.

D’Angelillo RM, Franco P, De Bari B, Fiorentino A, Arcangeli S, Alongi F

Crit Rev Oncol Hematol. 2015 Feb;93(2):136-48
2014

[The aging male: a global approach to late onset hypogonadism and erectile dysfunction].

Vlamopoulos Y, Jichlinski P, Tawadros T

Rev Med Suisse. 2014 Dec 3;10(453):2328-31

[Focal therapy in prostate cancer: rationale, results and perspectives].

Valerio M, Benamran D, Tawadros T, Cerantola Y, Meuwly JY, Lutchmaya-Flick C, Lhermitte B, Wirth G, Iselin C, Jichlinski P

Rev Med Suisse. 2014 Dec 3;10(453):2306-10

Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer.

Valerio M, Stricker PD, Ahmed HU, Dickinson L, Ponsky L, Shnier R, Allen C, Emberton M

Prostate Cancer Prostatic Dis. 2014 Dec;17(4):343-7

Focal therapy will become a standard option for selected men with localized prostate cancer.

Valerio M, Emberton M, Ahmed HU

J Clin Oncol. 2014 Nov 10;32(32):3680-1

The role of stereotactic ablative radiotherapy in oncological and non-oncological clinical settings: highlights from the 7th Meeting of AIRO–Young Members Working Group (AIRO Giovani).

Franco P, De Bari B, Ciammella P, Fiorentino A, Chiesa S, Amelio D, Pinzi V, Bonomo P, Vagge S, Fiore M, Comito T, Cecconi A, Mortellaro G, Bruni A, Trovò M, Filippi AR, Greto D, Alongi F, AIRO Giovani Italian Association of Radiation Oncology, Young Memb

Tumori. 2014 Nov-Dec;100(6):e214-9

Health technology assessment in evolution - focal therapy in localised prostate cancer.

Valerio M, Emberton M, Barret E, Eberli D, Eggener SE, Ehdaie B, Jichlinski P, Ward JF, Ahmed HU

Expert Rev Anticancer Ther. 2014 Nov;14(11):1359-67

Toxicity of stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: a potential comparison bias.

Arcangeli S, De Bari B, Alongi F

J Clin Oncol. 2014 Oct 20;32(30):3454

The role of focal therapy in the management of localised prostate cancer: a systematic review.

Valerio M, Ahmed HU, Emberton M, Lawrentschuk N, Lazzeri M, Montironi R, Nguyen PL, Trachtenberg J, Polascik TJ

Eur Urol. 2014 Oct;66(4):732-51

Re: Tumor target volume for focal therapy of prostate cancer–does multiparametric magnetic resonance imaging allow for a reliable estimation?: F. Cornud, G. Khoury, N. Bouazza, F. Beuvon, M. Peyromaure, T. Flam, M. Zerbib, P. Legmann and N. B. Delongcham

Valerio M, Ahmed HU

J Urol. 2014 Oct;192(4):1297-8

A prospective development study investigating focal irreversible electroporation in men with localised prostate cancer: Nanoknife Electroporation Ablation Trial (NEAT).

Valerio M, Dickinson L, Ali A, Ramachandran N, Donaldson I, Freeman A, Ahmed HU, Emberton M

Contemp Clin Trials. 2014 Sep;39(1):57-65

Comorbidity and nutritional indices as predictors of morbidity after transurethral procedures: A prospective cohort study.

Valerio M, Cerantola Y, Fritschi U, Hubner M, Iglesias K, Legris AS, Lucca I, Vlamopoulos Y, Vaucher L, Jichlinski P

Can Urol Assoc J. 2014 Sep;8(9-10):E600-4

Re: Jarow et al.: Drug and device development for localized prostate cancer: report of a Food and Drug Administration/American Urological Association public workshop (Urology 2014;83:975-979).

Valerio M, Emberton M, Ahmed HU

Urology. 2014 Sep;84(3):732-3

Choline-PET in prostate cancer management: the point of view of the radiation oncologist.

De Bari B, Alongi F, Lestrade L, Giammarile F

Crit Rev Oncol Hematol. 2014 Sep;91(3):234-47

Defining the level of evidence for technology adoption in the localized prostate cancer pathway.

Valerio M, El-Shater Bosaily A, Emberton M, Ahmed HU

Urol Oncol. 2014 Aug;32(6):924-30

From radiobiology to technology: what is changing in radiotherapy for prostate cancer.

De Bari B, Fiorentino A, Arcangeli S, Franco P, D’Angelillo RM, Alongi F

Expert Rev Anticancer Ther. 2014 May;14(5):553-64

Arachidonic acid induction of Rho-mediated transendothelial migration in prostate cancer.

Brown M, Roulson JA, Hart CA, Tawadros T, Clarke NW

Br J Cancer. 2014 Apr 15;110(8):2099-108

Salvage therapy of small volume prostate cancer nodal failures: a review of the literature.

De Bari B, Alongi F, Buglione M, Campostrini F, Briganti A, Berardi G, Petralia G, Bellomi M, Chiti A, Fodor A, Suardi N, Cozzarini C, Nadia DM, Scorsetti M, Orecchia R, Montorsi F, Bertoni F, Magrini SM, Jereczek-Fossa BA

Crit Rev Oncol Hematol. 2014 Apr;90(1):24-35

[Urology].

Jichlinski P

Rev Med Suisse. 2014 Jan 15;10(412-413):127-9

Changes in patterns of practice for prostate cancer radiotherapy in Italy 1995-2003. A survey of the Prostate Cancer Study Group of the Italian Radiation Oncology Society.

Pegurri L, Buglione M, Girelli G, Guarnieri A, Meattini I, Ricardi U, Mangoni M, Gabriele P, Bellavita R, Krengli M, Bonetta A, Cagna E, Bunkheila F, Borghesi S, Signor M, Di Marco A, Bertoni F, Stefanacci M, Gatta R, De Bari B, Magrini SM

Tumori. 2014 Jan-Feb;100(1):31-7
2013

[Prostate cancer center: a multidisciplinary approach to accurately manage patients with prostate cancer].

Tawadros T, Burruni R, Herrera F, Codeluppi C, Zurkinden C, Meuwly JY, Lhermitte B, Berthold D

Rev Med Suisse. 2013 Dec 4;9(409):2270-2, 2274

Salvage therapy of intraprostatic failure after radical external-beam radiotherapy for prostate cancer: a review.

Alongi F, De Bari B, Campostrini F, Arcangeli S, Matei DV, Lopci E, Petralia G, Bellomi M, Chiti A, Magrini SM, Scorsetti M, Orecchia R, Jereczek-Fossa BA

Crit Rev Oncol Hematol. 2013 Dec;88(3):550-63

Prostate cancer as a paradigm of multidisciplinary approach? Highlights from the Italian young radiation oncologist meeting.

De Bari B, Fiorentino A, Greto D, Ciammella P, Arcangeli S, Avuzzi B, D’Angelillo RM, Desideri I, Kirienko M, Marchiori D, Massari F, Fundoni C, Franco P, Filippi AR, Alongi F

Tumori. 2013 Nov-Dec;99(6):637-49

Can 3T multiparametric magnetic resonance imaging accurately detect prostate cancer extracapsular extension?

Cerantola Y, Valerio M, Kawkabani Marchini A, Meuwly JY, Jichlinski P

Can Urol Assoc J. 2013 Nov-Dec;7(11-12):E699-703

The “PROCAINA (PROstate CAncer INdication Attitudes) Project” (Part II)–a survey among Italian radiation oncologists on radical radiotherapy in prostate cancer.

De Bari B, Alongi F, Franco P, Ciammella P, Chekrine T, Livi L, Jereczek-Fossa BA, Filippi AR, AIRO Young and AIRO Prostate cancer Working Group.

Radiol Med. 2013 Oct;118(7):1220-39

Does hormone therapy modify the position of the gold markers in the prostate during irradiation? A daily evaluation with kV-images.

Udrescu C, De Bari B, Rouvière O, Ruffion A, Michel-Amadry G, Jalade P, Devonec M, Colombel M, Chapet O

Cancer Radiother. 2013 Jun;17(3):215-20

The PROCAINA (PROstate CAncer INdication Attitudes) Project (Part I): a survey among Italian radiation oncologists on postoperative radiotherapy in prostate cancer.

Alongi F, De Bari B, Franco P, Ciammella P, Chekrine T, Livi L, Jereczek-Fossa BA, Filippi AR, AIRO Young and AIRO Prostate cancer Working Group.

Radiol Med. 2013 Jun;118(4):660-78

[Immunotherapy: a therapeutic revolution against prostate cancer?].

Pracht M, Herrera F, Tawadros T, Berthold D

Rev Med Suisse. 2013 May 22;9(387):1070-5

Release of macrophage migration inhibitory factor by neuroendocrine-differentiated LNCaP cells sustains the proliferation and survival of prostate cancer cells.

Tawadros T, Alonso F, Jichlinski P, Clarke N, Calandra T, Haefliger JA, Roger T

Endocr Relat Cancer. 2013 Feb;20(1):137-49

[Urology. Trends in prostatic diseases in 2012].

Jichlinski P

Rev Med Suisse. 2013 Jan 16;9(369):147-9
2012
2011
2010